<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710797</url>
  </required_header>
  <id_info>
    <org_study_id>2020-FXY-405</org_study_id>
    <nct_id>NCT04710797</nct_id>
  </id_info>
  <brief_title>Lymphadenectomy in Early Ovarian Cancer</brief_title>
  <acronym>LOVE</acronym>
  <official_title>A Prospective Randomized Multicentre Trial for Lymphadenectomy in Early-stage Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of comprehensive staging surgery with no lymphadenectomy on survival and&#xD;
      quality of life in patients with early-stage ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Compare the efficacy and safety in patients with International Federation of&#xD;
      Gynecology and Obstetrics (FIGO) stage IA -IIA epithelial ovarian cancer, undergo completion&#xD;
      staging surgery including systematic pelvic and para-aortic lymphadenectomy versus&#xD;
      comprehensive staging surgery without lymphadenectomy.&#xD;
&#xD;
      OUTLINE: This is a randomized phase III multicenter study. Patients will receive&#xD;
      comprehensive staging surgery without Lymphadenectomy or completion staging surgery including&#xD;
      systematic pelvic and para-aortic lymphadenectomy, and the adjuvant chemotherapy will accord&#xD;
      to National Comprehensive Cancer Network (NCCN) guidelines. Patients are followed up every 3&#xD;
      months within the first 2 years, and then every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 656 patients will be recruited for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>comprehensive staging surgery with or without lymphadenectomy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS(Progression-free survival)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS(Overall Survival)</measure>
    <time_frame>From date of randomization until the date of death from any cause or date of last follow up, up to 100 mons</time_frame>
    <description>From date of randomization until the date of death from any cause or date of last follow up, whichever came first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of lymph node</measure>
    <time_frame>3 years</time_frame>
    <description>The recurrence rate in the retroperitoneal lymph nodes after primary surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL(Quality of life)</measure>
    <time_frame>Baseline, 6 months and 1 year after surgery</time_frame>
    <description>Quality of life before surgery, and at 6 months and 1 year after surgery in both groups will be evaluated using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>3 years</time_frame>
    <description>The difference of the rate of Postoperative complications between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">656</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Lymphadenectomy</condition>
  <arm_group>
    <arm_group_label>No Lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Comprehensive staging surgery with no Lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphadenectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy</intervention_name>
    <description>open or minimally invasive surgical approach&#xD;
cytologic examinations&#xD;
All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied&#xD;
BSO and hysterectomy&#xD;
For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered&#xD;
Omentectomy&#xD;
Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels&#xD;
The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve</description>
    <arm_group_label>Lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Comprehensive staging surgery with no Lymphadenectomy</intervention_name>
    <description>open or minimally invasive surgical approach&#xD;
cytologic examinations&#xD;
All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied&#xD;
BSO and hysterectomy&#xD;
For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered&#xD;
Omentectomy&#xD;
In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes</description>
    <arm_group_label>No Lymphadenectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged 18 years to 70 years.&#xD;
&#xD;
          2. Primary diagnosis of epithelial ovarian cancer FIGO stage IA-IIA ( recevive no prior&#xD;
             treatment or receive incomplete initial surgery)，with indications of adjuvant&#xD;
             chemotherapy：①High-grade serous carcinoma; ②Grade 3 endometrioid carcinoma; ③Clear&#xD;
             cell carcinoma; ④Grade 2 endometrioid carcinoma with capsule ruptured or pelvic&#xD;
             tissues extension ⑤Low-grade serous carcinoma、Grade 1 endometrioid carcinoma and&#xD;
             Mucinous carcinoma of the ovary with pelvic tissues extension.&#xD;
&#xD;
          3. Patients who have given their signed and written informed consent.&#xD;
&#xD;
          4. Good performance status (ECOG 0/1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non epithelial ovarian malignancies and borderline tumors.&#xD;
&#xD;
          2. Suspicious lymph nodes at preoperative radiological evaluation.&#xD;
&#xD;
          3. Intraoperative clinically suspicious lymph nodes (bulky nodes).&#xD;
&#xD;
          4. Secondary invasive neoplasms in the last 5 years (except synchronal endometrial&#xD;
             carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with&#xD;
             any signs of relapse or activity.&#xD;
&#xD;
          5. Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy.&#xD;
&#xD;
          6. Diseases of the lymph system (including lymph edema of unknown origin).&#xD;
&#xD;
          7. Prior retroperitoneal lymph node dissection (systematic or sampling).&#xD;
&#xD;
          8. Any other concurrent medical conditions contraindicating surgery.&#xD;
&#xD;
          9. Pregnancy.&#xD;
&#xD;
         10. Any reasons interfering with giving of informed consent , abiding by protocol, or&#xD;
             regular follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihong Liu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihong Liu, Ph.D.</last_name>
    <phone>86-20-87343102</phone>
    <email>liujih@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Deng, Ph.D.</last_name>
    <phone>86-20-87343105</phone>
    <email>dengting@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jihong Liu, Ph.D.</last_name>
      <phone>86-20-87343102</phone>
      <email>liujih@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ting Deng, Ph.D.</last_name>
      <phone>86-20-87343105</phone>
      <email>dengting@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jihong Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

